Roche Announces Positive Phase I Results Of CT-996 For Obesity Treatment
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Roche (RHHBY) announced positive results from two arms of an ongoing multi-part Phase I clinical trial for CT-996, an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-506997606-3aeda39d7c734e459725400f855c816d.jpg "Is Shopping at Big-Box Stores Worth It? Factors to Consider")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1169041231-5052d200552d467baab33417938984a3.jpg "10 Low-Risk Income Sources for a Safer Retirement")
:max_bytes(150000):strip_icc():format(jpeg)/business-team-investment-entrepreneur-trading-discussing-and-analysis-graph-stock-market-trading-stock-chart-concept-1089940388-acef8549576a4d918cb157c6c88ec8a1.jpg "Introduction to Phantom Stocks and SARs")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-991180154-aad62bea33e2473a808a24eb81b8e068.jpg "How the Minimum Wage Impacts Unemployment")
